ROIV Roivant Sciences
- 11.150
- +0.260+2.39%
- 11.471
- +0.321+2.88%
Roivant Sciences News
Bank of America Securities Reaffirms Their Hold Rating on Roivant Sciences (ROIV)
BofA Securities Maintains Roivant Sciences(ROIV.US) With Hold Rating
Roivant Sciences (ROIV) Receives a Buy From Leerink Partners
Roivant Sciences Analyst Ratings
TD Cowen Maintains Roivant Sciences(ROIV.US) With Buy Rating
H.C. Wainwright Maintains Roivant Sciences(ROIV.US) With Buy Rating, Maintains Target Price $18
TD Cowen Maintains Roivant Sciences(ROIV.US) With Buy Rating
TD Cowen Keeps Their Buy Rating on Roivant Sciences (ROIV)
Roivant Sciences (ROIV) Receives a Buy From TD Cowen
TD Cowen Maintains Roivant Sciences(ROIV.US) With Buy Rating
Leerink Partners Maintains Roivant Sciences(ROIV.US) With Buy Rating
Goldman Sachs Maintains Roivant Sciences(ROIV.US) With Buy Rating
Strong Buy Rating for Roivant Sciences Backed by Strategic Dermavant Divestiture and Promising Clinical Pipeline
H.C. Wainwright Maintains Roivant Sciences(ROIV.US) With Buy Rating, Maintains Target Price $18
Analysts Offer Insights on Healthcare Companies: Progyny (PGNY) and Roivant Sciences (ROIV)
Roivant Sciences Analyst Ratings
TD Cowen Maintains Roivant Sciences(ROIV.US) With Buy Rating
Jefferies Maintains Roivant Sciences(ROIV.US) With Buy Rating, Raises Target Price to $18
BofA Securities Maintains Roivant Sciences(ROIV.US) With Hold Rating, Maintains Target Price $12.5
TD Cowen Maintains Roivant Sciences(ROIV.US) With Buy Rating
No Data